Compare OVBC & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVBC | CRDL |
|---|---|---|
| Founded | 1872 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.0M | 226.6M |
| IPO Year | 1996 | 2017 |
| Metric | OVBC | CRDL |
|---|---|---|
| Price | $47.12 | $1.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.49 |
| AVG Volume (30 Days) | 15.1K | ★ 1.3M |
| Earning Date | 11-03-2026 | 11-12-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ 42.67 | N/A |
| EPS | ★ 1.53 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $30.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.18 | $0.88 |
| 52 Week High | $51.25 | $2.34 |
| Indicator | OVBC | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 64.43 | 26.44 |
| Support Level | $46.54 | $0.95 |
| Resistance Level | $47.05 | $1.35 |
| Average True Range (ATR) | 0.97 | 0.07 |
| MACD | 0.16 | 0.00 |
| Stochastic Oscillator | 85.05 | 10.05 |
Ohio Valley Banc Corporation is a financial holding company. The bank is a full-service financial institution offering a blend of commercial and consumer banking services in Southeastern Ohio and western West Virginia. The banking services offered by the bank include the acceptance of deposits in checking, savings, time and money market accounts; the making and servicing of personal, commercial, and student loans; and the making of construction and real estate loans. It also offers individual retirement accounts, safe deposit boxes, wire transfers, and other standard banking products and services.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.